Skip to main content

COVID-19

 

Clinical courses

 

Clinical courses

  • RA/SRF Posts at National Institute of Immunology

    The National Institute of Immunology, New Delhi, is a leading research Institute in India with a long-standing reputation for scientific excellence. The institute is equipped with state-of-the-art infrastructure for pursuing research in immunology and allied sciences. The Institute also imparts vigorous long-term research training leading to a Ph.D degree.

  • Recruitment for Pharmacists (6 posts) due to COVID-19 outbreak

    Walk in Interview (Novel Corona Virus (Covid - 19) It is therefore announced that, in order to meet the status of Novel Corona Virus (Covid 19), management of Anand District Hospitals and Covid Care Centers and treatment of Corona Virus sufferers below.  The said posts have to be filled for three months with fixed honorarium.

    Post : Junior Pharmacist

  • Biological E. Limited Gets CDSCO Nod to Start Phase III Clinical Trial of its COVID-19 Vaccine Candidate

    Biological E. Limited, a Hyderabad-based vaccine and pharmaceutical company announced that it has successfully completed the Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India and received the approval to start the Phase III clinical trial from the Central Drugs Standard Control Organization (CDSCO) - Subject Expert Committee (SEC).

  • Zydus receives Emergency Use Approval from DCGI for the use of Pegylated Interferon alpha-2b, Virafin

    Zydus Cadila announced that the company has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of  Virafin, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults. A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications.

  • Triangular-shaped spikes key to coronavirus transmission, finds new study

    COVID-19 needs no introduction. Last year, the disease, which is caused by the virus SARS-CoV-2, reached every continent across the globe. By the end of March 2021, there had been an estimated 128 million cases recorded with almost three million of these being fatal. As scientists' race to develop vaccines and politicians coordinate their distribution, fundamental research on what makes this virus so successful is also being carried out.

  • The sequence of pfizer & moderna mRNA COVID19 vaccines decoded by Stanford scientists and posted on github

    Stanford scientists saved drops of the COVID-19 vaccine destined for the garbage can, reverse engineered them, and have posted the mRNA sequence that powers the vaccine on GitHub for all to see.

  • Vacancy for Pharmacist at Jalgaon Municipal Corporation

    Jalgaon Municipal Corporation was founded in 21 march. 2003 & Smt.Ashatai Kolhe has become a first Leady Mayor of Jalgaon Municipal Corporation History. Jalgaon Municipal Corporation serves an area approximately 68.78 Sq.km. & provides civil services & facilities around the 4.60 Lacks people.

  • Tika Utsav is pivotal because we know that there is no proven medicine to combat COVID-19

    Tika Utsav is pivotal because we know that there is no proven medicine to combat COVID-19. We need to maintain 6 feet social distancing, wear the mask, regular hand washing, and regular sanitization, maintain a good diet and fitness, mentioned Dr. Manoj Nesari, Adviser (Ay.) Ministry of AYUSH, Govt. of India in the webinar organized by PHD Chamber of Commerce and Industry on Importance of TikaUtsav-Covid Vaccination.

  • Dr. Reddys Laboratories Gets Emergency Use Authorisation for Sputnik V in India

    Dr. Reddys Laboratories Ltd announced that it has received the permission from the Drug Controller General of India(DCGI)to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clincial Trials rules, 2019 under the Drugs and Cosmetics Act.

  • NIH begins study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines

    A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines. A systemic allergic reaction to a vaccine occurs in one or more parts of the body beyond the injection site.

Subscribe to COVID-19